All In Biotech

Drug Trial Radar · NCT06073132

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 4, 2024

Primary completion

Jun 10, 2026

Study completion Mar 2027

Sponsor

Lead sponsor
TWi Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

Conditions

  • Generalized Epidermolysis Bullosa Simplex

Interventions

  • AC-203Drug

    The investigational product is formulated as 1% topical ointment

  • VehicleDrug

    Vehicle-only control study medication is the same formulation as investigational product without active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving treatment success on the IGA of the Treatment Area, in which treatment success is defined as a score of 0 or 1 with at least a 2-point reductionTime frame: from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)

Locations

30 sites in 18 countries. Site status is shown where the registry gives one.

  • Mission dermatology Center

    Rancho Santa Margarita, California

  • Stanford University

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Northwestern University - Lurie Childrens's Hospital

    Chicago, Illinois

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Premier Specialists

    Kogarah, Australia

  • Sydney Children's Hospital

    Randwick, Australia

  • Universitaetsklinik fuer Dermatologie und Allergologie

    Salzburg, Austria

  • UZ Leuven

    Leuven, Belgium

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Hospital of Skin and Venereal Diseases of Thessaloniki

    Thessaloniki, Greece

  • Postgraduate Institute of Medical Education and Research (PGIMER)

    Chandigarh, India

  • Children's Health Ireland

    Dublin, Ireland

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano

    Milan, Italy

  • Università degli Studi di Modena e Reggio Emilia (UNIMORE)

    Modena, Italy

  • Istituto Dermopatico dell'Immacolata (IDI) - Istituto di

    Rome, Italy

  • UOS "Centro delle Dermatosi Croniche Complesse e Genodermatosi" UOC Dermatologia

    Rome, Italy

  • Hospital Tunku Azizah (Hospital Wanita Dan Kanak-kanak Kuala Lumpur)

    Kuala Lumpur, Malaysia

  • Asian Hospital

    City of Muntinlupa, Philippines

  • Iloilo Doctors Hospital

    Iloilo City, Philippines

  • Health Cube Medical Clinics

    Mandaluyong, Philippines

  • OT.CO Clinic Osipowicz & Turkowski

    Warsaw, Poland

  • Gangnam Severane Hospital

    Seoul, South Korea

  • Hospital Universitario La Paz

    Madrid, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Sheikh Khalifa Medical City (SKMC)

    Abu Dhabi, United Arab Emirates

  • Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust - Somers Clinical Research Facility (CRF)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.